10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
US drugmaker AbbVie’s hopes that Skyrizi (risankizumab) will help to replace revenues lost when Humira (adalimumab) competition starts to bite, have been boosted further. 11 June 2019
Tecentriq (atezolizumab) has been added to the UK’s Early Access to Medicines Scheme (EAMS) for use in combination with the chemotherapy agents carboplatin and etoposide, for the first-line treatment of adults with extensive-stage small cell lung cancer (SCLC). 11 June 2019
The US Food and Drug Administration has approved top-selling immuno-oncology drug Keytruda (pembrolizumab), under priority review, for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). 11 June 2019
Hopes for Novavax’s once highly-anticipated respiratory syncytial virus (RSV) shot, ResVax, were dealt a new blow on Monday, as the US regulator said an additional Phase III trial would be needed. 11 June 2019
A new biotech has been launched by GT Healthcare Capital Partners, a life science-focused private equity partnership specializing in capital investments and market scalability in the China region. 11 June 2019
US biotech major Celgene (Nasdaq: CELG) presented data from the first full readout of the APPRECIATE real-world evidence (RWE) study at the World Congress of Dermatology (WCD) in Milan. APPRECIATE is the largest RWE study of Otezla (apremilast), involving 480 patients across six European countries. 11 June 2019
Israeli microbiome company BiomX has licensed a new set of bacterial targets from JSR Corporation, for the development and commercialization of phage therapies for primary sclerosing cholangitis (PSC), an orphan liver disease. 11 June 2019
In the latest sign that the consumption of cannabis for medicinal purposes is being legitimized, the Church of England has reversed its previous policy of refusing to invest in schemes seeking to profit from the drug’s use. 11 June 2019
Shares in Roche were 2% higher by lunchtime on Tuesday following the US Food and Drug Administration (FDA) approval of the first chemo-immunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). 11 June 2019
New York-headquartered charity TB Alliance has announced a positive decision from the US regulator’s scientific advisory body, in relation to an investigational multidrug-resistant (MDR) tuberculosis therapy. 11 June 2019
Evotec has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis (TB). 11 June 2019
Danish cancer specialist and Darzalex (daratumumab) discoverer Genmab has inked a deal with its long-time partner Johnson & Johnson, to develop and commercialize a novel CD38 monoclonal antibody, HexaBody-CD38. 11 June 2019
Merck & Co has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases. 10 June 2019
California-based rare diseases specialist Eiger BioPharmaceuticals today announced the appointment of Mark Mannebach, as vice president of global regulatory affairs. 10 June 2019
In yet a further delay to the transaction, Swiss pharma giant Roche and Spark Therapeutics today announced that they have each received a request for additional information and documentary material from the US Federal Trade Commission (FTC) in connection with the agency’s review of Roche’s pending $4.3 billion acquisition of Spark announced in February this year. 10 June 2019
Chinese biotech firm CStone Pharmaceuticals today announced that the company has entered into a global clinical collaboration with China focus with Bayer HealthCare LLC, a unit of Germany’s Bayer. 10 June 2019
Immune-mediated disease specialist Provention Bio has presented data from the At-Risk study, testing its type 1 diabetes candidate PRV-031 (teplizumab). 10 June 2019
US drugmaker Vertex Pharmaceuticals is enhancing its gene editing capabilities to develop novel therapies for Duchenne muscular dystrophy (DMD) and myotonic dystrophy Type 1 (DM1) by expanding its collaboration with CRISPR Therapeutics (Nasdaq: CRSP) and acquiring Exonics Therapeutics. 8 June 2019
Despite a perceived lack of innovation that has moved the needle in the last five years, rheumatology remains a massively lucrative sector in which many of the world’s biggest pharma companies continue to earn the largest slice of their revenue. 7 June 2019
As the dust settles on this year’s annual meeting of the American Society of Clinical Oncology (ASCO), analysts have a lot of promising data to digest. 7 June 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024